by Paul | 29th April 2026 | News
Robert J. Dempsey, MBA, Chief Executive Officer, to present at Eyecelerator Raj Patil, PhD, Chief Scientific Officer, to present at ARVO London and New York, NY, April 29, 2026. OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing...
by Paul | 7th April 2026 | News
London and New York, NY, April 7, 2026. OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and for inflammatory eye diseases, today announced that it...
by Paul | 19th March 2026 | News
London and New York, NY, March 19, 2026. OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and for inflammatory eye diseases, today announced it has...
by Paul | 19th March 2026 | News
London and New York, NY, March 19, 2026. OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and for inflammatory eye diseases, today announced it has...
by Paul | 19th March 2026 | News
London and New York, NY, March 19, 2026. OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and for inflammatory eye diseases, today announced it has...
by Paul | 18th March 2026 | News
London and New York, NY, March 18, 2026. OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and for inflammatory eye diseases, today announced new...
